Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.54 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11687077 | 0.83 | CA1 (0.54) | AKR1C3AKR1C2F2RL1MEN1KMT2A | |
| SCHEMBL11684208 | 0.81 | RXRA (0.46) | AKR1C3MEN1KMT2AKDM4EPOLB | |
| SCHEMBL1988245 | 0.79 | AKR1C3 (0.49) | AKR1C3AKR1C2MAPK1RAB9AKDM4E | |
| SCHEMBL4294900 | 0.79 | SMN1; SMN2 (0.53) | AKR1C3AKR1C2MAPK1RAB9AKDM4E | |
| SCHEMBL8627436 | 0.79 | HPSE (0.50) | AKR1C3AKR1C2RAB9AKDM4EPOLB | |
| SCHEMBL7591665 | 0.78 | SMN1; SMN2 (0.51) | AKR1C3AKR1C2MEN1KMT2AUSP2 | |
| SCHEMBL2667003 | 0.78 | CA1 (0.51) | RAB9AKDM4EPOLB | |
| SCHEMBL2313019 | 0.77 | AKR1C3 (0.54) | AKR1C3AKR1C2MEN1KMT2ALMNA | |
| SCHEMBL17978141 | 0.77 | GPR183 (0.44) | FFAR1FFAR4 | |
| SCHEMBL2317055 | 0.77 | AKR1C3 (0.50) | AKR1C3AKR1C2LMNAMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328903-B1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | AKR1C3 102/4885AKR1C2 333/4885FPR2 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.